



I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 11th day of November, 2005.


(Signature of person mailing)

Carol A. Senn
(Typed or printed name of person)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:
DANILO GIRIBONE, ET AL.

APPLICATION NO.: 10/540,081 : Examiner: Not Yet Assigned

FILING DATE: JUNE 16, 2005 : Group Art Unit: 1614

TITLE: STABLE ISOTOPE-LABELED
CAMPTOTHECIN DERIVATIVES :
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicants herein make available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicants, copies of which are enclosed.


The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicants belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO/FB/A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12). A copy of the International Search Report from counterpart International Application No. PCT/EP03/14801 is also enclosed.

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445. A prompt and favorable response is earnestly solicited.

Date: November 11, 2005

Respectfully submitted,


David L. Kershner
Attorney for Applicant(s)
Reg. No. 53,112

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212) 733-0538

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY. DOCKET NO. PC27365				SERIAL NO. 10/540,081							
			APPLICANT DANILO GIRIBONE, ET AL.				FILING DATE JUNE 16, 2005 GROUP 1614							
U.S. PATENT DOCUMENTS														
EXAMINER INITIAL			DOCUMENT NUMBER				DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
WO	0	4	0	5	6	3	9	8	7/8/04	PCT			YES	NO
WO		0	1	2	1	2	1	9	2/29/01	PCT				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
			Slatter, J.G., et al., "Pharmacokinetics, Metabolism, and Excretion of Irinotecan (CPT-11) following I.V. Infusion of [¹⁴ C]CPT-11 in Cancer Patients", Drug Metabolism & Disposition; 2000, Vol. 28, No. 4, pgs 423-433.											
			Atsumi, R., et al., "Pharmacokinetics of SN-38 '(+)-(4S)-4,11-diethyl-4,9-dihydroxy-1H-pyrano '3', 4':6,7'-indolizino '1,2-b:quinoline-3, 14(4H, 12H)-dione', an active metabolite of irinotecan, after a single intravenous dosing of 14C-SN-38 to rats." Biological & Pharmaceutical Bulletin, Aug. 1995, Vol. 18, No. 8, pgs 1114-1119.											
			Hinz, H.R., et al., "Stabilities of <3>H- and <2>H-labelled camptothecins", Journal of Labelled Compounds and Radiopharmaceuticals, 1996, Vol. 38, No. 8, pgs 733-742.											
			Ronman, P.E., et al., "The Preparation of Tritium Labeled Camptothecin and Deuterium Labeled Camptothecin", Journal of Labelled Compounds and Radiopharmaceuticals, 1981, Vol. 18, No. 3, pgs 319-330.											
			Emerson, D.L., et al., "Antitumor efficacy, pharmacokinetics, and biodistribution of NX211:a low clearance liposomal formulation of lurtotecan", Clinical Cancer Research, July 2000, Vol. 6, No. 7, pgs 2903-2912.											
			Gabr, A., et al., "Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH", Cancer Research, Nov. 1997, Vol. 57, No. 21, pgs 4811-4816											
			Nicholas, A.W., et al., "Synthesis of position-specific tritium-labeled 20(S)-camptothecin, 9-amino-20(S)-camptothecin, and 10, 11-methylenedioxy-20(S)-camptothecin", Journal of Labelled Compounds and Radiopharmaceuticals, 1993, Vol. 33, No. 9, pgs 839-848											
EXAMINER			DATE CONSIDERED											
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														